

SEQUENCE LISTING

<110> Faustman Hayashi

<120> Methods for Treating and Diagnosing Autoimmune Disease

<130> MGH/Faustman 17633/1030

Attorney Representing Client:

Kathleen M. Williams, Ph.D.

Palmer and Dodge LLP

One Beacon Street

Boston, MA 02108

<140> 09/031,629

<141> 1998-03-27

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fluorogenic

<213> Artificial Sequence

<223> Description of Artificial Sequence: Fluorogenic

peptide used for degradation assays

<220>

<222> (3)

<223> 7-amido-4-methylcoumarin is attached to the C-terminal Arg

<220>

<221> SITE

<222> (1)

<223> The N-terminal Leu contains a tert-butyoxycarbonyl modification

<400> 2

Leu Arg Arg

1

<210> 3

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fluorogenic peptide used for degradation assays

<220>

<221> SITE

```
223> beta-napthylamide is attached to the C-terminal
      Glu
<220>
<221> SITE
<222> (1)
<223> The N-terminal Leu contains a carbenzoyx
      modification
<400> 3
Leu Leu Glu
  1
<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Heptapeptide
      from the carboxy-terminal domain of RNA polymerase
      II large subunit
<400> 4
```

1

Tyr Ser Pro Thr Pro Ser

5



<210> 5

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Probe for wild-type kappa B1 sequence

<400> 5

gatctaggga ctttccgctg gggactttcc ag

32

<210> 6

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Probe for wild-type kappa B2 sequence

<400> 6

gatctcaggg gaatctccct ctccttttat gggcgtagcg

40